Bank of America vs. JPMorgan Chase: Diverging Quarterly Revenue Trends for These Financial Giants
The report characterizes JPMorgan's business as having a strong year that appears to offset seasonal weakness. [[fact:fact-2vpg42jp5]] It describes Bank of America's revenue as largely stagnant. [[fact:fact-myou0cbmk]] JPMorgan is forecasting increased trading revenue and investment banking fees. [[fact:fact-w1so4q75q]] Bank of America expects its investment banking fees to decline. [[fact:fact-4an03v54h]] The data provider's standardized bank revenue metric adds interest income and non-interest income and does not deduct interest expense. [[fact:fact-nplxwiue0]]
Merck Rises 5% as Earnings Beat Lifts Profit Outlook; Eli Lilly Climbs 7%, Johnson & Johnson Edges Higher - Yahoo Finance
Merck Rises 5% as Earnings Beat Lifts Profit Outlook; Eli Lilly Climbs 7%, Johnson & Johnson Edges Higher - Yahoo Finance(摘要待生成)
Johnson & Johnson reports 94% success rate in trial of coronary artery device
Johnson & Johnson reports 94% success rate in trial of coronary artery device(摘要待生成)
Johnson & Johnson reports lower mortality rates with Impella heart pumps
Johnson & Johnson reports lower mortality rates with Impella heart pumps(摘要待生成)
Johnson & Johnson looking to buy eye disease biotech for up to $3.4bn
Johnson & Johnson looking to buy eye disease biotech for up to $3.4bn(摘要待生成)
Johnson & Johnson EVP sells $3.7M in shares after option exercise
Johnson & Johnson EVP sells $3.7M in shares after option exercise(摘要待生成)
Johnson & Johnson Sees a Path to Double-Digit Growth by 2030. Is the Dividend King a Buy?
Johnson & Johnson Sees a Path to Double-Digit Growth by 2030. Is the Dividend King a Buy?(摘要待生成)
Johnson & Johnson announces new Phase 2 nipocalimab study data in Sjögren's disease that reveal insights on importance of symptom improvements most valued by patients
Johnson & Johnson announces new Phase 2 nipocalimab study data in Sjögren's disease that reveal insights on importance of symptom improvements most valued by patients(摘要待生成)
Johnson & Johnson Just Took $7 Billion in Charges and Still Raised Its Outlook. Here's What That Tells Investors.
Johnson & Johnson Just Took $7 Billion in Charges and Still Raised Its Outlook. Here's What That Tells Investors.(摘要待生成)
强生拟以22亿美元现金收购Ollin Biosciences 另有最高11.25亿美元付款
强生拟以22亿美元现金收购Ollin Biosciences 另有最高11.25亿美元付款(摘要待生成)
强生拟斥资至多34亿美元收购眼科疾病生物科技公司
强生拟斥资至多34亿美元收购眼科疾病生物科技公司(摘要待生成)
强生公司pasritamig联合疗法在1期临床试验中取得73%的前列腺特异性抗原(PSA)应答率
强生公司pasritamig联合疗法在1期临床试验中取得73%的前列腺特异性抗原(PSA)应答率(摘要待生成)